论文部分内容阅读
目的比较硝普钠与酚妥拉明治疗冠心病合并心力衰竭的临床疗效。方法选取2014年2月—2016年2月贵港市人民医院收治的冠心病合并心力衰竭患者94例。随机将患者分为对照组与治疗组,各47例。对照组患者给予酚妥拉明治疗,治疗组患者给予硝普钠治疗,比较两组患者治疗前后的左心室射血分数、左心室舒张末直径、左心室收缩末直径、临床疗效、心功能指标恢复正常时间和治疗时间及不良反应发生情况。结果治疗前两组患者左心室射血分数、左心室舒张末直径、左心室收缩末直径比较,差异无统计学意义(P>0.05);治疗后治疗组患者左心室射血分数高于对照组,左心室舒张末直径、左心室收缩末直径小于对照组,差异有统计学意义(P<0.05);两组患者左心室射血分数高于治疗前,左心室舒张末直径、左心室收缩末直径小于治疗前,差异有统计学意义(P<0.05)。治疗组患者总有效率高于对照组,差异有统计学意义(P<0.05)。治疗组患者心功能指标恢复正常时间和治疗时间短于对照组,差异有统计学意义(P<0.05)。治疗组患者不良反应发生率低于对照组,差异有统计学意义(P<0.05)。结论硝普钠治疗冠心病合并心力衰竭的疗效优于酚妥拉明,其可有效改善患者心功能指标,缩短住院治疗时间,且不良反应少。
Objective To compare the clinical effects of sodium nitroprusside and phentolamine in the treatment of coronary heart disease complicated with heart failure. Methods 94 patients with coronary heart disease complicated with heart failure admitted to Guigang People’s Hospital from February 2014 to February 2016 were selected. Patients were randomly divided into control group and treatment group, 47 cases in each. Patients in the control group were treated with phentolamine. Patients in the treatment group were treated with sodium nitroprusside. Left ventricular ejection fraction, left ventricular end-diastolic diameter, left ventricular end-systolic diameter, clinical efficacy and cardiac function before and after treatment were compared between the two groups Return to normal time and treatment time and adverse reactions. Results There was no significant difference in left ventricular ejection fraction, left ventricular end-diastolic diameter and left ventricular end-systolic diameter between the two groups before treatment (P> 0.05). The left ventricular ejection fraction of the treatment group was higher than that of the control group , Left ventricular end diastolic diameter, left ventricular end systolic diameter less than the control group, the difference was statistically significant (P <0.05); two groups of patients with left ventricular ejection fraction higher than before treatment, left ventricular end diastolic diameter, left ventricular end-systolic The diameter was less than before treatment, the difference was statistically significant (P <0.05). The total effective rate of the treatment group was higher than that of the control group, the difference was statistically significant (P <0.05). The recovery time and treatment time of cardiac function in treatment group were shorter than those in control group, with significant difference (P <0.05). The incidence of adverse reactions in the treatment group was lower than that in the control group, the difference was statistically significant (P <0.05). Conclusion Sodium nitroprusside is superior to phentolamine in the treatment of coronary heart disease complicated with heart failure. It can effectively improve the cardiac function indexes and shorten the hospitalization time with fewer adverse reactions.